ReCognitION, a new 1.3 M€ European project under the leadership of Peter-Bram ‘t Hoen, Baziel van Engelen and Jeffrey Glennon, was kicked-off in Gent. ReCognitION is an acronym for Recognition and Validation of Druggable Targets from the response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from Integrated -Omics Networks. The project is built on the successful OPTIMISTIC clinical trial. The OPTIMISTIC trial showed a positive effect of lifestyle interventions on the social participation and physical activity of Myotonic Dystrophy patients. In ReCognitION, Radboudumc will work with partners in Gent, Paris, Prague and Ottawa to understand the molecular pathways underlying the response to cognitive behavioural therapy and to identify drugs targeting these pathways that may consolidate or reinforce the effect of cognitive behavioural therapy.
ReCognitION was funded by ZON-MW and similar national funding organisations in Belgium, France, the Czech Republic and Canada under the eRARE program.